Status:
RECRUITING
A Neurocognitive Study in Patients With Brain Oligometastases Receiving Hypofractionated SRT
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Brain Metastases, Adult
Eligibility:
All Genders
18-84 years
Brief Summary
Background: For newly-diagnosed patients with brain metastasis, conventional whole-brain radiation therapy (WBRT) might still remain a common palliative management even for those with brain oligometa...
Eligibility Criteria
Inclusion
- Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for postoperative adjuvant or therapeutic hypofractionated stereotactic radiotherapy (HF-SRT).
- A Fair/good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70.
- The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 4 cm shown on pre-radiotherapy MRI; namely, that is the clinical setting of oligometastatic brain disease or brain oligometastases.
Exclusion
- Patients with their primary cancer arising from hematological malignancies (i.e., malignant lymphomas, leukemia), germ cell tumors, or malignant meningiomas
- Patients with MRI-identified metastasis within 5 mm peri-hippocampally
- Patients with metastasis involving the brain stem
- Clinical suspicion of leptomeningeal spreading
- History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons
Key Trial Info
Start Date :
February 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 10 2027
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT04805255
Start Date
February 25 2021
End Date
March 10 2027
Last Update
May 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 333
2
Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 333